FDA Program Aims To Speed Review, Development Of COVID-19 Drugs

By Beth Wang / March 31, 2020 at 8:54 PM
FDA established a program to speed reviews of COVID-19 treatments and support research on COVID-19 drug candidates, the agency announced Tuesday (March 31). The Coronavirus Treatment Acceleration Program (CTAP) will provide rapid review of, and input on, drug and biologic development plans. FDA will quickly respond to requests for investigational drug access and work with applicants and other regulatory agencies to avoid supply disruptions by transferring manufacturing to alternative sites. FDA is triaging requests from developers of new drugs and...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.